Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Post-Therapeutic Tumor Losses of B-Cell Receptor Components CD20/CD19, a New Challenge in the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Thomas Hueso, Jessy Alchidiac, Maria-Rosa Ghigna, Arnaud Pages, Cyril Quivoron, Camille Bigenwald, Loic Renaud, Cristina Castilla-Llorente, Alexandre Eeckhoutte, Serge Bologna, Veronique Morel, Vincent Delwail, Pierre Feugier, Catherine Thieblemont, Olivier Bernard, Peggy Dartigues, Christophe Massard, Vincent Ribrag, Jean-Marie Michot

Blood (2024) 144 (Supplement 1): 474.

https://doi.org/10.1182/blood-2024-203664

Published: 2024

Journal Articles

Single-Cell Atlas of Diffuse Large B-Cell Lymphoma Reveals Integrated Malignant B Cell and Tumor Microenvironment Characteristics Associated with Clinical Response

Blood (2024) 144 (Supplement 1): 1597.

https://doi.org/10.1182/blood-2024-209815

Published: 2024

Journal Articles

CD20low/CD68high a Promising Microenvironnement Profile Identifying Classical Hodgkin Lymphoma Patients with Poor Outcome a Lysa Study

Alexandra Traverse-Glehen, Laurent Martin, Camille Laurent, Peggy Dartigues, Barbara Burroni, Diane Damotte, Marie Parrens, Herve Ghesquieres, Marguerite Fournier, Salim Kanoun, Anne Ségolène Cottereau, Marc Andre, Cédric Rossi, René-Olivier Casasnovas

Blood (2023) 142 (Supplement 1): 3011.

https://doi.org/10.1182/blood-2023-174784

Published: 2023

Journal Articles

A Single Cell Atlas of Diffuse Large B Cell Lymphomas Reveals Distinct Cellular States Predictive of Outcomes

Blood (2023) 142 (Supplement 1): 848.

https://doi.org/10.1182/blood-2023-173929

Published: 2023

Journal Articles

An unusual myelofibrosis

Véronique Vergé, Peggy Dartigues

Blood (2022) 140 (13): 1570.

https://doi.org/10.1182/blood.2022015663

Published: 2022

Journal Articles

Mutational landscape of gray zone lymphoma

Blood (2021) 137 (13): 1765–1776.

https://doi.org/10.1182/blood.2020007507

Published: 2021

Includes: Supplemental data

Journal Articles

High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Cyril Quivoron, PhD, Jean-Marie Michot, MD, Valérie Camara-clayette, PhD, Alina Danu, MD, Julien Lazarovici, MD, Clementine Sarkozy, MD PhD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Capucine Baldini, MD, Patricia Martin-Romano, MD PhD, Helene Lecourt, Veronique Vergé, MD, Andrea Varga, MD, Sophie Cotteret, MD PhD, Peggy Dartigues-Cuillères, MD, Christophe Massard, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-136114

Published: 2020

Journal Articles

Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project

Christiane Copie Bergman, MDPhD, Elodie Bohers, PhD, Peggy Dartigues-Cuillères, MD, Pierre-Julien Viailly, Philippe Ruminy, PhD, Vinciane Marchand, Marie-Helene Delfau-Larue, Corinne Haioun, MDPhD, Cyrielle Robe, Elsa Poullot, MD, Steven Le Gouill, MD PhD, Yannick Le Bris, PharmD, Céline Bossard, MD, Anne Moreau, MD, Vincent Ribrag, MD, Valérie Camara-clayette, PhD, Cyril Quivoron, PhD, Gilles Salles, MDPhD, Sophie Cotteret, MD PhD, Pierre Sujobert, MD PhD, Alexandra Traverse-Glehen, MD PhD, Claire Mauduit, Pascaline Etancelin, Sarah Huet, Liana Veresezan, MD, Krimo Bouabdallah, MD, Marie Parrens, MD, Audrey Gros, PhD, Samuel Amintas, David Sibon, MD PhD, Ludovic Lhermitte, MD PhD, Thomas Steimle, Sophie Kaltenbach, Bettina Fabiani, MD, Camille Laurent, MD PhD, Barbara Burroni, Laurent Martin, MD PhD, Thierry Jo Molina, MDPhD, Lysa LYSARC study group, Fabrice Jardin, MD PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-141953

Published: 2020

Journal Articles

Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?

Jean-Marie Michot, MD, Valérie Camara-Clayette, PhD, Cyril Quivoron, PhD, Alina Danu, MD, Julien Lazarovici, MD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Capucine Baldini, MD, Patricia Martin-Romano, MD PhD, Clementine Sarkozy, MD PhD, Andrea Varga, MD, Helene Lecourt, Veronique Vergé, MD, Sophie Cotteret, MD PhD, Peggy Dartigues-Cuillères, MD, Christophe Massard, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136134

Published: 2020

Journal Articles

Sub-Cutaneous Rituximab-Minichop Versus Sub-Cutaneous Rituximab-Minichop + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More (SENIOR Study). a Multicentric Randomized Phase III Study of the Lysa

Lucie Oberic, MD, Mathieu Puyade, MD, Frederic Peyrade, MD, Herve Maisonneuve, MD, Julie Abraham, Pierre Feugier, MD, Catherine Thieblemont, MD PhD, Gilles Salles, MD PhD, Fontanet Bijou, MD, Gian-Matteo Pica, MD, Philippe Ruminy, PhD, Peggy Dartigues-Cuillères, MD, Gandhi Damaj, MD PhD, Philippe Gaulard, MD PhD, Jean-François Emile, MD PhD, Bettina Fabiani, Herve Tilly, MD PhD, Corinne Haioun, MD PhD, Fabrice Jardin

Blood (2019) 134 (Supplement_1): 352.

https://doi.org/10.1182/blood-2019-123612

Published: 2019

Journal Articles

Molecular Characterisation of Diffuse Large B Cell Lymphoma in Patients of 80 Years Old or More: Clinical Relevance in a Multicentric Randomized Phase III Study of the Lysa (SENIOR Study)

Blood (2019) 134 (Supplement_1): 2765.

https://doi.org/10.1182/blood-2019-124444

Published: 2019

Journal Articles

Comparative Study of Tumor Biopsy and Ctdna to Support Patient Selection in Phase I Trials: The Gustave Roussy Single Center Experience in Aggressive B-Cell Lymphomas

Anthony Tarabay, MD, Jean-Marie Michot, MD, Anne Aupérin, Julien Lazarovici, Julien Rossignol, MD PhD, David Ghez, MD PhD, Peggy Dartigues-Cuillères, MD, Veronique Vergé, Vincent Ribrag, MD, Christophe Massard, Valérie Camara-clayette

Blood (2019) 134 (Supplement_1): 1496.

https://doi.org/10.1182/blood-2019-127170

Published: 2019

Journal Articles

Non-Effectiveness of Using RICE Post RDHAP or RDHAP Post RICE after Failure of First Line Salvage Therapy in DLBCL Patients Who Are Eligible for ASCT

Tony Ibrahim, MD MSc, Tarek Assi, Julien Lazarovici, MD, Maxime Annereau, PharmD, David Ghez, MD PhD, Jean-Marie Michot, MD, Julia Arfi-Rouche, Julien Rossignol, MD PhD, Veronique Vergé, Jacques Bosq, Peggy Dartigues-Cuillères, MD, Alina Danu, MD, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 4226.

https://doi.org/10.1182/blood-2018-99-117444

Published: 2018

Journal Articles

Follicular Lymphoma Grade 3A Exhibits Pathological and Cytogenetic Diversity, but Similar Prognosis Compared to FL Grade 1-2: Pooled Analysis of 1757 Follicular Lymphomas from the PRIMA and Relevance Trials

Camille Laurent, MD PhD, Danielle Canioni, MD, Bettina Fabiani, MD, Véronique Meignin, Catherine Chassagne-Clément, MD, Peggy Dartigues-Cuillères, MD, Christiane Copie, MDPhD, Guillaume Cartron, Franck Morschhauser, MD, Gilles Salles, MD PhD, Luc Xerri, MD PhD

Blood (2018) 132 (Supplement 1): 778.

https://doi.org/10.1182/blood-2018-99-115831

Published: 2018

Journal Articles

Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 4110.

https://doi.org/10.1182/blood-2018-99-110852

Published: 2018

Journal Articles

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy

Blood (2018) 132 (1): 49–58.

https://doi.org/10.1182/blood-2017-11-816405

Published: 2018

Includes: Supplemental data

Journal Articles

Prognostic Value of P53 and Myc Protein Expression in Follicular Lymphomas in the PRIMA Trial in the Lysa Group

Danielle Canioni, MD, Laure Joseph, MD, Bettina Fabiani, MD, Catherine Chassagne-Clément, MD, Peggy Dartigues-Cuillères, MD, Frederic Charlotte, MD, Pauline Brice, MD, Pierre Feugier, MD, Franck Morschhauser, MD PhD, Anne Sonet, MD, Gilles Salles, MD PhD, Luc Xerri, MD PhD

Blood (2017) 130 (Supplement 1): 1508.

https://doi.org/10.1182/blood.V130.Suppl_1.1508.1508

Published: 2017

Journal Articles

Discovery and Validation of a Simplified Scoring System (the PRIMA-Prognostic Index) in De Novo Follicular Lymphoma Treated Initially with Immunochemotherapy

Blood (2017) 130 (Supplement 1): 413.

https://doi.org/10.1182/blood.V130.Suppl_1.413.413

Published: 2017

Journal Articles

The Combination of High Expression of CD68-Positive Tumor-Associated Macrophages and PET2-Positivity Predicts Unfavorable Outcome in Patients with Classical Hodgkin Lymphoma Treated in the Lysa AHL2011 Study

Blood (2016) 128 (22): 1825.

https://doi.org/10.1182/blood.V128.22.1825.1825

Published: 2016

Journal Articles

Management and Outcomes of Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Retrospective Study By the Lymphoma Study Association

Julien Lazarovici, MD, Pauline Brice, MD, Lucie Obéric, MD, Isabelle Gaillard, MD, Mathilde Hunault-Berger, MD PhD, Florence Broussais, MD, Serge Bologna, MD, Emmanuel Gyan, MD PhD, Catherine Sebban, MD, Mohamed Touati, MD, Richard Delarue, MD, Frédérique Orsini-Piocelle, MD, Aspasia Stamatoullas, MD, Peggy Dartigues, MD, Marc PE André, MD, Olivier Casasnovas, MD, Nicolas Mounier, MD PhD, Christophe Fermé, MD

Blood (2014) 124 (21): 3054.

https://doi.org/10.1182/blood.V124.21.3054.3054

Published: 2014

NARROW

Post-Therapeutic Tumor Losses of B-Cell Receptor Components CD20/CD19, a New Challenge in the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Single-Cell Atlas of Diffuse Large B-Cell Lymphoma Reveals Integrated Malignant B Cell and Tumor Microenvironment Characteristics Associated with Clinical Response

CD20low/CD68high a Promising Microenvironnement Profile Identifying Classical Hodgkin Lymphoma Patients with Poor Outcome a Lysa Study

A Single Cell Atlas of Diffuse Large B Cell Lymphomas Reveals Distinct Cellular States Predictive of Outcomes

An unusual myelofibrosis

Mutational landscape of gray zone lymphoma

High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project

Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?

Sub-Cutaneous Rituximab-Minichop Versus Sub-Cutaneous Rituximab-Minichop + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More (SENIOR Study). a Multicentric Randomized Phase III Study of the Lysa

Molecular Characterisation of Diffuse Large B Cell Lymphoma in Patients of 80 Years Old or More: Clinical Relevance in a Multicentric Randomized Phase III Study of the Lysa (SENIOR Study)

Comparative Study of Tumor Biopsy and Ctdna to Support Patient Selection in Phase I Trials: The Gustave Roussy Single Center Experience in Aggressive B-Cell Lymphomas

Non-Effectiveness of Using RICE Post RDHAP or RDHAP Post RICE after Failure of First Line Salvage Therapy in DLBCL Patients Who Are Eligible for ASCT

Follicular Lymphoma Grade 3A Exhibits Pathological and Cytogenetic Diversity, but Similar Prognosis Compared to FL Grade 1-2: Pooled Analysis of 1757 Follicular Lymphomas from the PRIMA and Relevance Trials

Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy

Prognostic Value of P53 and Myc Protein Expression in Follicular Lymphomas in the PRIMA Trial in the Lysa Group

Discovery and Validation of a Simplified Scoring System (the PRIMA-Prognostic Index) in De Novo Follicular Lymphoma Treated Initially with Immunochemotherapy

The Combination of High Expression of CD68-Positive Tumor-Associated Macrophages and PET2-Positivity Predicts Unfavorable Outcome in Patients with Classical Hodgkin Lymphoma Treated in the Lysa AHL2011 Study

Management and Outcomes of Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Retrospective Study By the Lymphoma Study Association

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only